DP
PCRX icon

DW Partners’s Pacira BioSciences PCRX Stock Holding History

DW Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-64,500
Closed -$2.7M – 11
2015
Q3 		$2.7M Buy
64,500
+30,000
+87% +$1.84M 1.96% 11
2015
Q2 		$2.41M Buy
+34,500
New +$2.72M 0.72% 30

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DW Partners's PCRX Position: Q4 2015 in Review

DW Partners sold out of Pacira BioSciences (PCRX) in Q4 2015, closing a stake of 64,500 shares — an estimated $2.7M sold.

DW Partners first reported a position in PCRX in Q2 2015 and held it in 2 quarters. The position peaked at $2.7M in Q3 2015. 214 funds tracked by Wall St. Rank hold PCRX as of Q4 2015.

  • DW Partners reported no remaining Pacira BioSciences position as of Q4 2015 after selling out during the quarter.
  • DW Partners sold 64,500 Pacira BioSciences shares in Q4 2015, an estimated $2.7M.
  • DW Partners first reported a position in Pacira BioSciences in Q2 2015 and held it in 2 quarters.
  • DW Partners's Pacira BioSciences position peaked at $2.7M in Q3 2015.
  • 214 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2015.

Based on DW Partners's 13F filing for Q4 2015, filed 12 Feb 2016.